This collection examines Europe’s harm reduction journey, including early successes, uneven implementation, securitisation, stigma and medicalisation; and proposes a reframed, people-led approach centring wellbeing, acknowledging drug-use benefits, and advancing rights-based reforms.
IDPC joins civil society worldwide in calling on Canada to reaffirm its leadership in global health by pledging CAD$1.37 billion to the Global Fund, saving millions of lives and strengthening global resilience.
WHO underscores opioid agonist maintenance treatment (OAMT) as an essential, lifesaving health service, providing practical strategies to prevent and manage disruptions, safeguard access to methadone and buprenorphine, and ensure continuity of care during crises and instability.
At UNGA 80, global leaders unite to expose how punitive drug policies harm women’s health and equality and to advance gender-responsive, rights-based reforms that uphold justice and health.
International cooperation through the Association of Southeast Asian Nations presents an opportunity to consistently align regional drug policy with human rights standards.
The WHO ECDD reviews the coca leaf’s chemistry, pharmacology, and uses, noting potential therapeutic effects, low toxicity, and weak evidence of dependence potential.
The CSFD calls for an EU Drugs Strategy that puts health, human rights and equity at its core — moving from political statements to real action, with civil society as a full partner.
UNODC presents its perspective on the role of treaty flexibilities in enabling decriminalisation as part of health-based approaches, identifying related reforms and alternatives to punitive measures.
Against criminalisation, invisibility and systemic violence, these initiatives seek to expand gender-responsive harm reduction and policy reform, based on lived experience.
C-EHRN urges the European Commission to reconsider its decision to eliminate EU4Health operating grants, warning that it endangers vital public health and human rights protections.
